GlassScriptPhysician profile
Parvinderjit Khanuja
NPI 1053385765
$11,894.77
in general payments reported to CMS, 2019-2025
59 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,928 · 2020: $483 · 2021: $757 · 2022: $1,468 · 2023: $2,887 · 2024: $1,366 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158 · Travel and Lodging: $981 · Education: $99.99 · Gift: $20.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.95 |
| Travel and Lodging | $981.07 |
| Education | $99.99 |
| Gift | $20.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Specialty Care Distribution, LLC | $2,345.00 | 2019 | |
| US Oncology Corporate, INC. | $1,633.44 | 2023 | |
| Genentech USA, INC. | $655.78 | 2019-2025 | Polivy, Alecensa, Gavreto |
| Pfizer INC. | $637.28 | 2019-2025 | |
| Celgene Corporation | $553.76 | 2019-2025 | Reblozyl, Opdualag |
| Abbvie INC. | $552.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $439.43 | 2019-2025 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $363.52 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $283.11 | 2019-2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $281.74 | 2019-2025 | |
| Janssen Biotech, INC. | $273.78 | 2019-2024 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $222.58 | 2019-2024 | Opdivo |
| Daiichi Sankyo INC. | $204.61 | 2019-2025 | Enhertu, Vanflyta |
| Astellas Pharma US INC | $185.30 | 2019-2024 | Xtandi, Padcev, Xospata |
| Springworks Therapeutics, INC. | $177.45 | 2024-2025 | Ogsiveo |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvinderjit Khanuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.